Pancytopenia Associated with Salazosulfapyrizine Therapy in a Boy with Systemic Type Juvenile Rheumatoid Arthritis.
|
Accession number;02A0351398
|
| Title;Pancytopenia Associated with Salazosulfapyrizine Therapy in a Boy with Systemic Type Juvenile Rheumatoid Arthritis. |
| Author;
NAKAHATA TOORU
(Iwatekenkitakamibyoin Shonika)
HIRANO KOJI
(Iwatekenkitakamibyoin Shonika)
ITO RYOSUKE
(Iwatekenkitakamibyoin Shonika)
ONODERA NORIO
(Iwatekenkitakamibyoin Shonika)
TANAKA HIROSHI
(Hirosaki Univ., Sch. of Med.)
WAGA SHINOBU
(Hirosaki Univ., Sch. of Med.)
|
Journal Title;Journal of the Japan Pediatric Society
|
Journal Code:F0896A
|
ISSN:0001-6543
|
|
VOL.106;NO.4;PAGE.492-495(2002)
|
| Figure&Table&Reference;FIG.1, TBL.1, REF.16 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;A boy aged four years with systemic type juvenile rheumatoid arthritis (JRA) was referred to our hospital because of high fever. Although he had been treated with prednisolone (PSL), tolmetin, auranofin and mizoribine, he developed refractory JRA. Then, administration of salazosulfapyridine (SASP) was started ten days before admission. Laboratory tests at the presentation revealed thrombocytopenia and an increased level of C-reactive protein. Bone marrow aspiration showed severe hypoplastic marrow: nuclear cell count 45,500/.MU.l, megakaryocyte 0/.MU.l. Soon after discontinuation of the medication except for PSL, his bone marrow suppression rapidly improved. Although a lymphocyte stimulation test for SASP was negative, SASP is most likely the causative agent for his hypoplastic bone marrow, from the clinical course in which administration of this agent led to an episode of thrombocytopenia with recovery on its removal. SASP has been safely used in the treatment of JRA to date; however, there are few reports to describe its myelotoxicity in JRA patients. We, therefore, suggest that SASP be considered a potential cause of bone marrow suppression in the treatment of JRA. (author abst.) |
|
|
|
Related Articles;
|
|
